What was the primary driver for the increase in net sales?

The increase in net sales for the six months ended June 30, 2005, was primarily driven by strong unit growth across key product lines and segments, as well as a favorable impact from the relatively weaker U.S. dollar which boosted international sales. Acquisitions, such as TheraSense and EAS, also contributed to the sales growth.

What caused the decrease in gross profit margin?

The decrease in gross profit margin was attributed to several factors, including an unfavorable product mix, particularly with increased sales of Boehringer Ingelheim products which have lower margins. Additionally, lower sales of Synthroid due to generic competition and the unfavorable impact of currency exchange rates on gross profit margins contributed to the decline.

How did the spin-off of Hospira affect the financial statements?

The spin-off of Hospira, Inc., which occurred on April 30, 2004, resulted in the income and cash flows of Hospira being presented as discontinued operations for the periods impacted. The financial statements reflect the hospital products segment and portions of the international segment that were part of the spin-off as discontinued operations.

What is Abbott's outlook regarding litigation and environmental matters?

Abbott has reserved approximately $35 million for litigation and environmental exposures as of June 30, 2005. While it is not feasible to predict the outcome of all proceedings with certainty, management believes that their ultimate disposition should not have a material adverse effect on the company's financial position, cash flows, or results of operations.

ABT 10-Q Quarterly Report Q2 FY2005 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported strong financial performance for the second quarter and the first six months of 2005, demonstrating robust top-line growth across its key segments. Net sales increased significantly, driven by unit growth and favorable foreign exchange rates. The company also saw substantial growth in operating earnings, indicating effective cost management and operational efficiency. The pharmaceutical and diagnostics segments were particularly strong performers, showcasing continued product demand and strategic market positioning. Despite a decrease in gross profit margin compared to the prior year, primarily attributed to product mix and the impact of certain distribution agreements, Abbott's overall financial health remains solid. The company generated substantial cash flow from operations and maintained a strong liquidity position. Management also proactively addressed potential future costs by announcing restructuring plans and continuing to manage litigation and environmental exposures, with no expected material adverse effects on the company's financial position.

Key Highlights

1Net sales for the first six months of 2005 grew by 16.7% to $10.9 billion, compared to $9.3 billion in the same period of 2004.
2Operating earnings for the first six months of 2005 increased by 27.7% to $2.23 billion, compared to $1.75 billion in the prior year.
3Diluted earnings per share from continuing operations for the six months ended June 30, 2005, were $1.09, up from $0.89 in the comparable period of 2004.
4The Pharmaceutical Products segment showed strong growth, with net sales up 18.7% for the first six months of 2005.
5The Diagnostic Products segment also performed well, with net sales increasing 14.8% for the first six months of 2005.
6Abbott made significant contributions to its defined benefit and post-employment medical/dental plans in the first six months of 2005, impacting operating cash flow.
7The company announced restructuring plans in July 2005, anticipating after-tax charges of approximately $215 million in the second half of 2005 and into 2006.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2005

Summary

Key Highlights

Frequently Asked Questions